Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 356
- Registration Number
- NCT01890473
- Locations
- 🇺🇸
Physician Research Collaboration, Llc, Lincoln, Nebraska, United States
🇿🇦Local Institution, George, Western Cape, South Africa
🇺🇸Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 489
- Registration Number
- NCT01860976
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Seattle Rheumatology Associates, Seattle, Washington, United States
🇺🇸St. Paul Rheumatology, P.A., Eagan, Minnesota, United States
Methotrexate-Inadequate Response Autoinjector Device Sub Study
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT01844895
Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT01835470
- Locations
- 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan
Abatacept as GVHD Prophylaxis Phase 2
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT01743131
- Locations
- 🇺🇸
Michael Grimley, Cincinnati, Ohio, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States
A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3
- Registration Number
- NCT01693640
- Locations
- 🇺🇸
NYU Center for Musculoskeletal Care, New York, New York, United States
Real-world Clinical Efficacy of Abatacept in the T3 Data Registry
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Arthritis Northwest PLLC
- Target Recruit Count
- 200
- Registration Number
- NCT01555879
- Locations
- 🇺🇸
Arthritis Northwest, Spokane, Washington, United States
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2011-11-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01339481
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
🇺🇸Arthritis Research of Florida, Palm Harbor, Florida, United States
Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis
- Conditions
- Interventions
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Julian M. Mackay-Wiggan
- Registration Number
- NCT01314495
Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 25
- Registration Number
- NCT01299961
- Locations
- 🇺🇸
UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.